Evidence map›Paper›PMID 36482103›Full record

Trial reportNature medicine2022

Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.

Andreas Hagen Røssevold, Nikolai Kragøe Andresen, Christina Annette Bjerre, Bjørnar Gilje, Erik Hugger Jakobsen, Sunil Xavier Raj, Ragnhild Sørum Falk, Hege Giercksky Russnes, Thea Jahr, Randi Ruud Mathiesen and 7 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03164993 (ALICE), which is not on this map. Cited by 66 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 12 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03164993 phase2completednot on this map

ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer

TypeinterventionalSponsorOslo University HospitalRan2017 to 2023Enrolled68ConditionsCancer, Breast, Triple Negative Breast CancerArmsAtezolizumab, Pegylated liposomal doxorubicin, Cyclophosphamide, Placebo
3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 12 syntheses or guidelines pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Efficacy and safety of a combination treatment of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Review
  19. Review
  20. Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 2 countries.

Andreas Hagen RøssevoldDepartment of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-7212-0111
Nikolai Kragøe AndresenDepartment of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0001-9386-1368
Christina Annette BjerreDepartment of Oncology, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-0530-8090
Bjørnar GiljeDepartment of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway.
Erik Hugger JakobsenDepartment of Oncology, Sygehuset Lillebælt, Vejle, Denmark.
Sunil Xavier RajDepartment of Oncology, St. Olav University Hospital, Trondheim, Norway.
Ragnhild Sørum FalkOslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.
Hege Giercksky RussnesDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Thea JahrDepartment of Radiology and Nuclear medicine, Oslo University Hospital, Oslo, Norway.
Randi Ruud MathiesenDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Jon LømoDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Øystein GarredDepartment of Pathology, Oslo University Hospital, Oslo, Norway.
Sudhir Kumar ChauhanDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Ragnhild Reehorst LereimDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Claire DunnDepartment of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Bjørn NaumeDepartment of Oncology, Oslo University Hospital, Oslo, Norway.
Jon Amund KyteDepartment of Clinical Cancer Research, Oslo University Hospital, Oslo, Norway. jonky@ous-hf.no.ORCID http://orcid.org/0000-0002-2854-3694
Oslo University Hospital · NOLillebaelt Hospital · DKRigshospitalet · DKStavanger University Hospital · NOSt Olav's University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1

Indexed as

AnthracyclinesTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCyclophosphamideDouble-Blind MethodHumansAnthracyclinesAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenCyclophosphamide

Identifiers

PMID36482103
PMCPMC9800277
OpenAlexW4310965676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.